Product Code: RP-ID-10347506 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Chemicals |
Report ID: 10347506
Market Overview:
Global NTRK Fusion Gene Positive Advanced Solid Tumors Market Size study, by Type (By Therapeutics, By Diagnostics), by End user (Hospitals and Clinics, Cancer Centers, Others), and Regional Forecasts 2020-2027
Global NTRK Fusion Gene Positive Advanced Solid Tumor market is anticipated to grow with a CAGR of nearly 5.4%, during the forecast period 2020-2027. NTRK fusion gene positive cancers are those in which the NTRK gene has been mutated. While NTRK fusions are uncommon, accounting for less than 1% of solid tumors, the exact prevalence is unknown. NTRK fusion genes can be detected using DNA Next Generation Sequencing (NSG) technology. It has a high level of sensitivity and accuracy. It is capable of detecting gene partners with significant therapeutic effects. Foundation One does not detect NTRK fusions using commercially available techniques such as DNA NGS panels. Due to technological advances, the global NTRK fusion gene positive advanced solid tumors market is expected to expand rapidly over the forecast period. The demand for NTRK fusion gene positive advanced solid tumors would benefit from early screening and identification of NTRK mutation genes in people. Due to the advancement of new therapeutics in the near future for treating various forms of cancers, the global NTRK fusion gene positive advanced solid tumours market has a high potential. NTRK inhibitors, such as Entrectinib, marketed by Genentech Inc., were recently licensed by the FDA in 2019, for the treatment of NTRK fusion gene positive advanced solid tumors. Likewise,, SeraCare Life Sciences, a foremost in vitro diagnostics producer and clinical laboratory partner, launched an extended neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion reference material panel in 2018, established in collaboration with Bayer. However, Poor healthcare infrastructure and high costs associated with genetic screening of NTRK fusion genes may hamper growth of NTRK fusion gene positive advanced solid tumors market growth over the forecast period of 2020-2027.
The regional analysis of the global NTRK Fusion Gene Positive Advanced Solid Tumors Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share due to rising cancer clinical research and development activities in the region. Whereas Europe is also anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027, due to early diagnosis and treatment adoption across the region.
Major market player included in this report are:
Bayer AG
Teva Pharmaceuticals
Empire Genomics, LLC.
SeraCare Life Sciences
F. Hoffmann-La Roche Ltd
NeoGenomics Laboratories, Inc.
Glaxosmithkline plc
Merck & Co.
Daiichi Sankyo Company Limited
S Deciphera Pharmaceuticals, Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
By Therapeutics
By Diagnostics
By end user:
Hospitals and Clinics
Cancer Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027.
Target Audience of the Global NTRK Fusion Gene Positive Advanced Solid Tumors Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Teva Pharmaceuticals
Empire Genomics, LLC.
SeraCare Life Sciences
F. Hoffmann-La Roche Ltd
NeoGenomics Laboratories, Inc.
Glaxosmithkline plc
Merck & Co.
Daiichi Sankyo Company Limited
S Deciphera Pharmaceuticals, Inc.
Related Reports
Proof of Quality & Reliability
